Clinical Trial Details


Research Study Summary

A phase 2, multicenter, double-blind placebo-controlled comparator study of 2 doses of LY2140023 versus placebo in patients with DSM-IV-TR Schizophrenia.


The primary purpose of your participation in this study is to help answer the following research question(s), and not to provide you treatment for your condition:

  • Whether LY2140023 can help subjects/patients with schizophrenia.
  • Whether LY2140023 can help subjects/patients with schizophrenia who have certain DNA.
You must be willing and able to stay in the hospital for a minimum of 21 days.

Please contact Alexian Brothers for more information on participation.

To Learn more

CW ID: 176870
Date Last Changed: July 22, 2013

Clinical Trial Snapshot

Both Male and Female
Overall Status
21 Days
Facility Type


Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
Phone: 847-230-3599

View Map

Research Center Information:

Alexian Brothers Hospital Network

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.